Trial Profile

A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Tolerability of ATSN-201 Gene Therapy in Male Subjects With RS1-Associated X-linked Retinoschisis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 May 2025 According to an Atsena Therapeutics media release, Interim results from Part A of the study were presented at the 2025 Association for Research in Vision and Ophthalmology and 2025 American Society for Gene and Cell Therapy annual meetings.
19 May 2025 According to an Atsena Therapeutics media release, Enrollment is underway in Part B, The pediatric cohort will be dosed after evaluating preliminary data from the adult cohort in Part B.
19 May 2025 Interim results presented in the Atsena Therapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com